PHIO Phio Pharmaceuticals Corp.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1533040 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-84.5%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-159.0%
ROA-128.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets23.8%
Debt / equity0.00x
Current ratio—
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.84x
Accruals ratio-19.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $3.06M | $3.08M | $2.79M | $1.48M | $1.18M | $1.07M | $886,000 | $985,000 |
| SG&A expense | $1.21M | $1.19M | $1.37M | $1.06M | $1.32M | $1.24M | $986,000 | $689,000 |
| Operating income | -$4.27M | -$4.27M | -$4.17M | -$2.53M | -$2.50M | -$2.31M | -$1.87M | -$1.67M |
| Interest expense | — | — | — | — | — | — | -$125,000 | — |
| Net income | -$4.16M | -$4.14M | -$4.00M | -$2.37M | -$2.39M | -$2.17M | -$1.77M | -$1.63M |
| EBITDA | -$4.27M | -$4.27M | -$4.17M | -$2.53M | -$2.50M | -$2.31M | -$1.87M | -$1.67M |
| EPS (basic) | -0.36 | -0.36 | -0.34 | — | -0.44 | -0.45 | -0.41 | — |
| EPS (diluted) | — | — | — | — | — | -0.45 | -0.41 | — |
| Weighted avg. shares (diluted) | — | — | — | — | — | 4.79M | 4.31M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $10.61M | $13.00M | $17.03M | $21.03M | $10.71M | $10.78M | $13.28M | $5.38M |
| Current assets | $11.31M | $14.30M | $17.40M | $21.48M | $11.49M | $11.29M | $13.44M | $5.74M |
| PP&E, net | $7,000 | $9,000 | $10,000 | $11,000 | $12,000 | $7,000 | $4,000 | $2,000 |
| Total assets | $11.32M | $14.31M | $17.41M | $21.49M | $11.51M | $11.30M | $13.44M | $5.74M |
| Current liabilities | — | — | — | — | — | $1.21M | $1.27M | $1.01M |
| Total liabilities | $2.70M | $1.71M | $950,000 | $1.34M | $1.67M | $1.21M | $1.27M | $1.01M |
| Shareholders' equity | $8.62M | $12.60M | $16.46M | $20.15M | $9.84M | $10.10M | $12.17M | $4.72M |
| Shares outstanding | 11.95M | 11.62M | 11.62M | 11.62M | 5.78M | 4.80M | 4.78M | 1.73M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.28M | -$4.04M | -$4.00M | -$2.08M | -$2.08M | -$2.54M | -$1.27M | -$1.37M |
| Capital expenditure | $0 | $0 | $0 | $0 | $7,000 | $3,000 | $2,000 | $1,000 |
| Free cash flow | -$2.28M | -$4.04M | -$4.00M | -$2.08M | -$2.09M | -$2.54M | -$1.28M | -$1.37M |
| Investing cash flow | $0 | $0 | $3,000 | $0 | -$7,000 | -$3,000 | -$2,000 | $8,000 |
| Financing cash flow | -$107,000 | $0 | $0 | $12.40M | $2.02M | $40,000 | $9.17M | $1.35M |
| Depreciation & amortization | $2,000 | $1,000 | $1,000 | $1,000 | $2,000 | $0 | $0 | $0 |
| Stock-based compensation | $285,000 | $278,000 | $318,000 | $274,000 | $113,000 | $51,000 | $43,000 | $48,000 |
Free plan shows the latest 8 periods; Pro shows all 62 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.